Manuscripts

Highlighted publications

Published Manuscripts

  1. Coombs L, Orlando A, Wang X, Shaw P, Rich AS, Lakhtakia S, Titchener K, Adamson B, Miksad RA, Mooney K. A machine learning framework supporting prospective clinical decisions applied to risk prediction in oncology. NPJ digital medicine. 2022 Aug 16;5(1):1-9.
  2. Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, Crown W. Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. Value in Health. 2022 Jul 1;25(7):1063-80.
  3. Ulrich AK, Adamson BJ, Saldarriaga EM, De La Grecca R, Wood D, Babigumira JB, Sanchez JL, Lama JR, Dimitrov D, Duerr A. Finding and treating early-stage HIV infections: A cost-effectiveness analysis of the Sabes study in Lima, Peru. The Lancet Regional Health-Americas. 2022 Aug 1;12:100281.
  4. Wang X, Adamson BJ, Briggs A, Tan K, Bargo D, Ghosh S, Baxi S, Ramsey S. Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. Value in Health. 2022 Feb 1;25(2):230-7.
  5. Massey D, Saydah S, Adamson B, Lincoln A, Aukerman D, Berke E, Sikka R, Krumholz H. Prevalence of COVID-19 and Long COVID in Collegiate Student Athletes from Spring 2020 to Fall 2021: A Retrospective Survey. medRxiv. 2022 Jan 1.
  6. Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and rapid antigen test results when infectious: a December 2021 occupational case series. medRxiv. Preprint posted online. 2022 Jan;5.
  7. Adamson BJS, Ma X, Griffith SD, Sweeney EM, Sarkar S, Bourla AB. Differential frequency in imaging-based outcome measurement: Bias in real-world oncology comparative-effectiveness studies. Pharmacoepidemiol Drug Saf. 2021 Jul 5. doi: 10.1002/pds.5323. PMID: 34227170.
  8. Adamson BJS, Cohen AB, Gross CP, Estévez M, Magee K, Williams E, Meropol NJ, Davidoff AJ. ACA Medicaid expansion association with racial disparity reductions in timely cancer treatment. Am J Manag Care. 2021 Jul;27(7):274-281. doi: 10.37765/ajmc.2021.88700. PMID: 34314116.
  9. Sikka R, Lincoln AE, Adamson BJ, Epstein JA, Krumholz HM, on behalf of the COVID Sports and Society Working Group. Reopening Lessons from the Big Leagues’ Experiences with COVID-19. Journal of Bone and Joint Surgery. 16 Nov 2020; ePub ahead of print. doi: 10.2106/JBJS.20.01894
  10. Ramsey S, Adamson BJ, Wang X, Bargo D, Baxi SS, Ghosh S, Meropol NJ. Using Electronic Health Record Data to Identify Comparator Populations for Comparative Effectiveness Research. Journal of Medical Economics. 2020 Nov 10;1-5. Online ahead of print. doi: 10.1080/13696998.2020.1840113.
  11. Bennette C, Lyons H, Wagner B, Adamson BJ, Change S, on behalf of the IDM COVID-19 Response Team. Inequitable availability of COVID-19 clinical trials for Hispanic populations in the United States. Institute for Disease Modeling InfoHub Pre-Print. 19 Aug 2020.
  12. Kerrigan KC et al. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clinical Lung Cancer. Jan 2021. DOI: https://doi.org/10.1016/j.cllc.2021.01.013.
  13. Castellanos EH, Orlando A, Ma X, Parikh RB, O’Connell G, Meropol NJ, Hamrick J, Adamson BJ. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment. JCO Oncology Practice. 4 Jun 2020. doi: 10.1200/JOP.19.00747
  14. Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. The Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice. 17 Jul 2020. doi: 10.1200/OP.20.00010
  15. Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR. MedRxiv. doi: medRxiv 2020.03.16.20037143.
  16. Parikh RB*, Adamson BJS*, Khozin S, Galsky MD, Baxi SS, Cohen AB, Mamtani R. Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer. JAMA. 2019;322(12):1209-1211. doi:10.1001/jama.2019.10650. *Co-first authors contributed equally to this study.
  17. Parikh RB, Feld E, Galsky M, Adamson B, Cohen C, Baxi S, Christodouleas J, Vaughn D, Meropol N, Mamtani R. First-line Immune Checkpoint Inhibitor Use in Cisplatin-Eligible Patients with Advanced Urothelial Carcinoma. Future Oncology. 16 Dec 2019. 16 (02), 4341-4345. doi: 10.2217/fon-2019-0578.
  18. Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D. Potential competition between biomedical HIV prevention strategies in Seattle, WA. Journal of the International AIDS Society. 2019 Aug 10; 22(8):e25373. doi:10.1002/jia2.25373
  19. Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R. Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. European Urology. 2019 Jul 27. pii: S0302-2838(19)30591-3. doi: 10.1016/j.eururo.2019.07.032. PMID: 31362898.
  20. Dimitrov D, Wood D, Ulrich A, Swan D, Adamson BJS, Lama J, Sanchez J, Ann Duerr D. Projected Effectiveness of HIV Detection During Early Infection and Rapid ART Initiation among MSM and Transgender Women in Peru: A Modeling Study. Infectious Disease Modeling. 2019 Apr 6;4:73-82. doi: 10.1016/j.idm.2019.04.001. PMID: 31025025
  21. Selinger C, Bershteyn A, Dimitrov D, Adamson B, Revill P, Hallett T, Phillips A, Bekker LG, Rees H, Gray G, and the P5 Global Access Committee. Targeting and Vaccine Durability Are Key for Population-level Impact and the Cost-Effectiveness of a Pox-Protein HIV Vaccine Regimen in South Africa. Vaccine. Volume 37, Issue 16, 10 April 2019, Pages 2258-2267. doi: 10.1016/j.vaccine.2019.02.073; PMID: 30890385.
  22. Adamson B, Lipira L, Katz A. The Impact of ACA and Medicaid Expansion on Progress Toward UNAIDS 90-90-90 Goals. Current HIV/AIDS Reports.Current HIV/AIDS Reports. Feb 2019, Volume 16, Issue I, pp 105-112. doi: 10.1007/s11904-019-00429-6.
  23. El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA (2019) Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond BOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). Front. Oncol. 2019, 9:142. doi: 10.33889/fonc.2019.00142; PMID: 30923702.
  24. Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson J, Garrison L, Donnell D. The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. Value in Health, 22 (2019) 194e202. DOI: https://doi.org/10.1016/j.jval.2018.09.001; PMID: 30711064 [Highlighted in: PharmacoEcon Outcomes News (2018) 816: 15. DOI: https://doi/10.1007/s40274-018-5435-8].
  25. Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R. Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life. The Oncologist. 2019;24:1-3. DOI: 10.1634/theoncologist.2019-0039; PMID: 30944183.
  26. de Montigny S, Adamson B, Masse B, Garrison L, Kublin J, Gilbert P, Dimitrov D. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. Nature Scientific Reports. 2018 Apr; 8(6066):1-12. doi:10.1038/s41598-018-24268-4; PMID: 29666455.  Listen to a clip of my interview about this paper on BBC World Service here. 
  27. Zimmermann M, Adamson B, Lam-Hine T, Rennie T, Stergachis A. Assessment Tool for Establishing Local Pharmaceutical Manufacturing in Low- and Middle-Income Countries. International Journal of Pharmacy Practice. 2018 Aug;26(4):364-368. doi: 10.1111/ijpp.12455; PMID: 29732641
  28. Adamson B, Carlson J, Kublin J, Garrison L. The Potential Cost‐Effectiveness of Pre-exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines 2017, 5(2), 13; doi:10.3390/vaccines5020013; PMID: 28538691.
  29. Adamson B, Dimitrov D, Devine D, Barnabas R. The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review. PharmacoEconomics Open (2017). DOI: 10.1007/s41669-016-0009-9 [Highlighted in: Several types of models predict HIV vaccines cost effective. PharmacoEcon Outcomes News (2017) 771: 29. doi:10.1007/s40274-017-3740-2]
  30. Adamson B, Fuchs J, Sopher C, Flood D, Johnson RP, Haynes B, Kublin J. A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines. Clinical and Translational Science. 2015 Apr;8(2):166-8. doi: 10.1111/cts.12249
  31. Sopher CJ, Adamson BJS, Andrasik MP, Flood DM, Wakefield SF, Stoff DM, Cook RC, Kublin JG, Fuchs JD. Enhancing Diversity in the Public Health Research Workforce: the Research and Mentorship Program (RAMP) for Future HIV Vaccine Scientists. Am J Public Health. 2015 April; 105(4): 823–830. doi: 10.2105/AJPH.2014.302076 Epub 2014 Dec 30.